Virology

CRO Expertise

Vaccine Development

HSV-1 AND HSV-2 INFECTION MODELS

RESPIRATORY SYNCYTIAL VIRUS (RSV)

Recognized expertise in infectious disease

OTHER INFECTION MODELS AVAILABLE

Webinars

Casey Maguire, Harvard Medical School – Strategies for in vivo Barriers to Gene Therapy Vectors

Jeffrey Vick, Chameleon Biosciences Inc. – Chameleon’s EVADER Technology: A more potent AAV vector with less immune response

Miguel Muñoz-Alía, Mayo Clinic – Retargeting and Shielding Measles Virus Vectors for Oncolytic Virotherapy

Technical Sheets

Vaccine Development

Articles

A mucosal vaccination approach for herpes simplex virus type 2.
KTirabassi, R.S., Ace, C., Levchenko, T.S., Torchilin, V.P., Selin, L.K., Nie, S., Guberski, D.L., Yang, K. Vaccine 29 (2011) 1090-1098.

Mucosal vaccines against respiratory syncytial virus
Kejian Yang and Steven M Varga; Current Opinion in Virology 2014, 6:78–84.